Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model.

Using an improved system for the functional identification of active antisense fragments, we have isolated antisense fragments which inactivate the p53 tumour suppressor gene. These antisense fragments map in two small regions between nt 350 and 700 and nt 800 and 950 of the coding sequence. These antisense fragments appear to act by inhibition of p53 mRNA translation both in vivo and in vitro. Expression of these antisense fragments overcame the p53-induced growth arrest in a cell line which expresses a thermolabile mutant of p53 and extended the in vitro lifespan of primary mouse embryonic fibroblasts. Continued expression of the p53 antisense fragment contributed to immortalisation of primary mouse fibroblasts. Subsequent elimination of the antisense fragment in these immortalised cells led to restoration of p53 expression and growth arrest, indicating that immortal cells continuously require inactivation of p53. Expression of MDM2 or SV40 large T antigen, but not E7 nor oncogenic ras, overcomes the arrest induced by restoration of p53 expression. Functional inactivation of both p21 and bax (by overexpression of Bcl2), but not either alone, allowed some bypass of p53-induced growth arrest, indicating that multiple transcriptional targets of p53 may mediate its antiproliferative action. The ability to conditionally inactivate and subsequently restore normal gene function may be extremely valuable for genetic analysis of genes for which loss-of-function is involved in specific phenotypes.

[1]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[2]  S. Syrjänen,et al.  New concepts on the role of human papillomavirus in cell cycle regulation. , 1999, Annals of medicine.

[3]  G. Hannon,et al.  MaRX: An Approach to Genetics in Mammalian Cells , 1999, Science.

[4]  R. Brown,et al.  p53-oriented cancer therapies: current progress. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  D. Wynford‐Thomas Cellular senescence and cancer , 1999, The Journal of pathology.

[6]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[7]  S. Lowe,et al.  Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.

[8]  G. Mills,et al.  Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition , 1997, Oncogene.

[9]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[10]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[11]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[12]  I. Roninson,et al.  Identification of p53 genetic suppressor elements which confer resistance to cisplatin , 1997, Oncogene.

[13]  J. Blaydes,et al.  Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. , 1996, Oncogene.

[14]  D. Wazer,et al.  Mutant p53-induced immortalization of primary human mammary epithelial cells. , 1996, Cancer research.

[15]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[16]  L. Gollahon,et al.  Immortalization of human mammary epithelial cells transfected with mutant p53 (273his). , 1996, Oncogene.

[17]  E. Androphy,et al.  Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells , 1996, Journal of virology.

[18]  I. Mazo,et al.  Genetic suppressor elements: new tools for molecular oncology--thirteenth Cornelius P. Rhoads Memorial Award Lecture. , 1995, Cancer research.

[19]  R. Reddel,et al.  Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts , 1995, Molecular and cellular biology.

[20]  G. Stein,et al.  Origins of G1 arrest in senescent human fibroblasts , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[21]  D. Lane p53 and human cancers. , 1994, British medical bulletin.

[22]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[23]  J. Barrett,et al.  Genetic and molecular basis for cellular senescence. , 1993, Advances in experimental medicine and biology.

[24]  D. Denhardt,et al.  Mechanism of Action of Antisense RNA. Sometime Inhibition of Transcription, Processing, Transport, or Translation a , 1992, Annals of the New York Academy of Sciences.

[25]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[26]  C. Finlay,et al.  What the papers say: p53 Loss of Function: Implications for the Processes of Immortalization and Tumorigenesis , 1992 .

[27]  J. Shay,et al.  The two-stage mechanism controlling cellular senescence and immortalization , 1992, Experimental Gerontology.

[28]  I. Roninson,et al.  Isolation of dominant negative mutants and inhibitory antisense RNA sequences by expression selection of random DNA fragments. , 1992, Nucleic Acids Research.

[29]  A. Rhodes,et al.  Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. , 1990, The Journal of general virology.

[30]  P. Palese,et al.  Expression of antisense RNA fails to inhibit influenza virus replication , 1989, Virus Research.

[31]  J. Mol,et al.  Antisense genes in plants: an overview. , 1988, Gene.

[32]  G. Stark,et al.  Excess antisense RNA from infectious recombinant SV40 fails to inhibit expression of a transfected, interferon-inducible gene. , 1988, European journal of biochemistry.

[33]  B. Wold,et al.  Stable reduction of thymidine kinase activity in cells expressing high levels of anti-sense RNA , 1985, Cell.

[34]  H. Weintraub,et al.  Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. , 1985, Science.

[35]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.